TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19700194

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg at baseline and months 1, 3, and 5)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Focal/grid laser photocoagulation (at baseline and month 3 if needed)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab (0.5 mg) and focal/grid laser (at baseline and month 3)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Focal/grid laser photocoagulation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab and focal/grid laser
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 126

Group type: COMPARATOR
Intervention: Focal/grid laser
Number of subjects: 126
Study: 16436842

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 176
Study: 15596352

Group type: EXPERIMENTAL
Intervention: Thickened infant formula with lactase activity
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 109
Study: 11122217

Group type: COMPARATOR
Intervention: Placebo (20 subjects, study group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BDP (10 subjects, control group)
Number of subjects: 30
Study: 9404431

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 80 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 85 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 90 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatments
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Monotherapy in the 80 mmHg target group
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Bitherapy in the 85 mmHg target group (France)
Number of subjects: 18790
Study: 8453217

Group type: EXPERIMENTAL
Intervention: Elective red cell transfusion to maintain capillary haematocrit greater than 0.35 l/1 (group 1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No transfusion (group 2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 19
Study: 3705896

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg) mixed with 10 ml of orange juice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline mixed with 10 ml of orange juice
Number of subjects: 40
Study: 30336337

Group type: EXPERIMENTAL
Intervention: High poverty neighborhoods
Number of subjects: 632

Group type: COMPARATOR
Intervention: Low poverty neighborhoods
Number of subjects: 632
Study: 29019855

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Donor milk (DM) / Infant formula (IF)
Number of subjects: 40
Study: 27055283

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Rapid Screening Tool (FiRST)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Correlation with total FiRST score
Number of subjects: 770
Study: 24667753

Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 50

Group type: COMPARATOR
Intervention: High oleic sunflower (HOS) oil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 50
Study: 22466383

Group type: EXPERIMENTAL
Intervention: Exercise program (100 two-footed jumps with a rope and standardized muscle strength exercise) for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 54
Study: 20619212

Group type: EXPERIMENTAL
Intervention: Video and booklet intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Any part of the intervention (video or booklet)
Number of subjects: 158
Study: 19194534

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: PCI (highest tertile risk)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Medical therapy alone (highest tertile risk)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2201
Study: 16084851

Group type: EXPERIMENTAL
Intervention: Tacrolimus (N = 30)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclosporine (N = 10)
Number of subjects: 40
Study: 11929046

Group type: EXPERIMENTAL
Intervention: Porphyria cutanea tarda patients
Number of subjects: 111

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 111
Study: 10430114

Group type: EXPERIMENTAL
Intervention: Accelerated titration regimen of sotalol (80 mg every 6 hours for four doses, then 160 mg every 12 hours for nine doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard titration regimen of sotalol (80 mg every 6 hours for eight doses, then 160 mg every 12 hours for nine doses)
Number of subjects: 34
Study: 7756495

Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g intravenous dose)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Cefotetan (1-g intravenous dose)
Number of subjects: 511
Study: 2405040

Group type: EXPERIMENTAL
Intervention: Furosemide (approximately 28 mg) administered by inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6947990

Group type: EXPERIMENTAL
Intervention: Preventive treatment (instruction and practice in oral hygiene techniques and meticulous prophylaxis) repeated every 2-3 months
Number of subjects: 555

Group type: COMPARATOR
Intervention: Traditional dental care (control group)
Number of subjects: 555
Study: 30612892

Group type: EXPERIMENTAL
Intervention: Three-dimensional balance training using visual feedback
Number of subjects: 24
Study: 27684425

Group type: EXPERIMENTAL
Intervention: Oral colostrum priming (OCP)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No oral colostrum priming (Control)
Number of subjects: 99
Study: 25930097

Group type: EXPERIMENTAL
Intervention: Linear EUS
Number of subjects: 278

Group type: COMPARATOR
Intervention: Radial EUS
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Second EUS examination
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 278
Study: 23757082

Group type: EXPERIMENTAL
Intervention: One 1‐hour on‐site clinician education session followed by 1 year of personalized, quarterly audit and feedback of prescribing for bacterial and viral ARTIs
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 162
Study: 21366943

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS) and 6% hydroxyethyl starch (HES) 130/0.4
Number of subjects: 135
Study: 19647715

Group type: EXPERIMENTAL
Intervention: Olyset net (2% permethrin treated long-lasting insecticidal net)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated net
Number of subjects: 0

Group type: COMPARATOR
Intervention: No net area
Number of subjects: 0
Study: 17804989

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30
Study: 15484347

Group type: EXPERIMENTAL
Intervention: High-risk distal polyps (size > or = 10 mm, or > or = 3 adenomas, or villous component > 20 percent, or severe dysplasia)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Low-risk distal polyps (1-2 tubular adenomas, < 10 mm, with low-grade dysplasia, or hyperplastic polyp)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Low-risk distal polyps (6 to 9 mm)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: High-risk distal polyps
Number of subjects: 426
Study: 11977312

Group type: EXPERIMENTAL
Intervention: Serum copper (Cu) level in measles patients during acute period
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Serum copper (Cu) level in measles patients during convalescence (3 weeks after regression of clinical symptoms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy persons aged 15-19)
Number of subjects: 26
Study: 9043506

Group type: EXPERIMENTAL
Intervention: Catheter Valve (CV)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Leg-Bag (LB)
Number of subjects: 18
Study: 7837153

Group type: EXPERIMENTAL
Intervention: Active Takayasu's arteritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody to purified 38-kDa protein of M. tuberculosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody to 65-kDa HSP of M. leprae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (tuberculosis positive controls, normal donors, patients with Wegener's granulomatosis)
Number of subjects: 0
Study: 2905991

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 30080735

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control (without FS)
Number of subjects: 586
Study: 27765912

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 342
Study: 25049140

Group type: EXPERIMENTAL
Intervention: Behavioural activation treatment (up to 12 sessions)
Number of subjects: 40
Study: 22652535

Group type: EXPERIMENTAL
Intervention: Extended daily diafiltration (EDDF)
Number of subjects: 7
Study: 20524719

Group type: EXPERIMENTAL
Intervention: rosuvastatin/fenofibric acid 20 mg/135 mg
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: rosuvastatin/fenofibric acid 10 mg/135 mg
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: rosuvastatin/fenofibric acid 5 mg/135 mg
Number of subjects: 474

Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 474
Study: 18581961

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparotomic surgery
Number of subjects: 20
Study: 16463989

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study: 12209085

Group type: COMPARATOR
Intervention: No maintenance medications
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Greater severity of asthma
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Atopy (increased IgE and allergy skin test reactivity)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Positive skin test response to dog and high level of dog allergen in the home
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Positive skin test response to cat and high level of cat allergen in the home
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Mean daily symptom code and use of albuterol for asthma symptoms
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Mean daily symptom code and daily use of albuterol
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Mean evening peak flow percentage of personal best
Number of subjects: 1041
Study: 10604095

Group type: EXPERIMENTAL
Intervention: Electromyography assessment of external anal sphincter
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Defaecographic findings
Number of subjects: 32
Study: 7565455

Group type: EXPERIMENTAL
Intervention: HOSS Ca (900 mg Ca/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (900 mg Ca/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2187614

Group type: EXPERIMENTAL
Intervention: Reformulated Dioralyte (RD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Dioralyte (SD)
Number of subjects: 32
Study: 6156321

Group type: EXPERIMENTAL
Intervention: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water loading
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water deprivation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prostaglandin A1 (PGA1) infusion with hypertonic mannitol during water deprivation
Number of subjects: 10
Study: 31937251

Group type: EXPERIMENTAL
Intervention: Novel telephone-delivered intervention involving educational aspects for patients and information-based intervention for physicians.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (historical control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel telephone-delivered intervention.
Number of subjects: 0
Study: 30277455

Group type: EXPERIMENTAL
Intervention: Supplemental Cr (0.05 mg Cr as Cr-methionine/kg of BW0.75)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no supplemental Cr)
Number of subjects: 48
Study: 28317678

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 34

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 34

Group type: COMPARATOR
Intervention: PRK with higher preoperative HOAs
Number of subjects: 34

Group type: COMPARATOR
Intervention: PRK with lower preoperative HOAs
Number of subjects: 34
Study: 27236602

Group type: EXPERIMENTAL
Intervention: 450 IU gonadotropins
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 300 IU gonadotropins
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 150 IU gonadotropins plus letrozole
Number of subjects: 95
Study: 24697948

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer SES
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Durable polymer SES
Number of subjects: 1192
Study: 22314121

Group type: EXPERIMENTAL
Intervention: nano-formulated diclofenac 18 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nano-formulated diclofenac 35 mg
Number of subjects: 30
Study: 19147724

Group type: EXPERIMENTAL
Intervention: Citrullinated myelin detection using (1)H-MR spectroscopy in patients with MS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal-appearing white matter (NAWM) in patients with MS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic demyelinating lesions (CDLs) in patients with MS
Number of subjects: 27
Study: 17504894

Group type: EXPERIMENTAL
Intervention: Pramlintide (up to 240 microg, self-administered via sc injection three times a day for 16 weeks)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 15608387

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) to common whelk
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Specific IgE detection by ELISA
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: ELISA inhibition test
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: IgE-immunoblotting
Number of subjects: 1700
Study: 11680663

Group type: EXPERIMENTAL
Intervention: Intermittent on-line predilution hemodiafiltration (IHDF)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both IHDF and IHD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall hospital mortality
Number of subjects: 39
Study: 9842252

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% eye drops, one drop each eye, four times daily for 8 weeks
Number of subjects: 35
Study: 7855939

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Linsidomine chlorhydrate (SIN‐1)
Number of subjects: 20
Study: 2775153

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behaviour therapy (ICBT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behaviour therapy (GCBT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behaviour therapy (ICBT) vs Group cognitive‐behaviour therapy (GCBT)
Number of subjects: 45
Study: 799975

Group type: EXPERIMENTAL
Intervention: Diftalone 500 mg per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Indomethacin 75 mg per day
Number of subjects: 32
Study: 31664441

Group type: EXPERIMENTAL
Intervention: Severe energy restriction (65%-75%) for 4 months followed by moderate energy restriction (25%-35%) for 8 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Moderate energy restriction (25%-35%) for 12 months
Number of subjects: 101
Study: 28826627

Group type: EXPERIMENTAL
Intervention: PENFS (percutaneous electrical nerve field stimulation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham (no electrical charge)
Number of subjects: 115
Study: 24838782

Group type: EXPERIMENTAL
Intervention: Congruence Couple Therapy (CCT) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (three brief check-ins over 12 weeks)
Number of subjects: 30
Study: 23062489

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50mg daily for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 48
Study: 21320954

Group type: EXPERIMENTAL
Intervention: Early treatment (ET)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 370
Study: 18664712

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of methylphenidate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 16438758

Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 5 microg sufentanil
Number of subjects: 54
Study: 15178178

Group type: EXPERIMENTAL
Intervention: Changes in semantic association to a stimulus during trials using fMRI and PET
Number of subjects: 0
Study: 10757456

Group type: EXPERIMENTAL
Intervention: cold solution (2-3 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hot solution (55-58 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: room temperature solution (20-21 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: lactose solution (50 g)
Number of subjects: 10
Study: 9351617

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice a day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 1609547

Group type: EXPERIMENTAL
Intervention: CVD 908 Salmonella typhi vaccine strain (5 x 10(7) organisms with sodium bicarbonate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVD 908 Salmonella typhi vaccine strain (5 x 10(4) to 5 x 10(7) organisms with sodium bicarbonate)
Number of subjects: 0
Study: 4047872

Group type: EXPERIMENTAL
Intervention: Progressive Intensification and Progressive Decrease in Intensification of stimulation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Expectation of series without objective stimuli
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All items of the scale
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Scale of Sensory Suggestibility
Number of subjects: 81
Study: 31937608

Group type: EXPERIMENTAL
Intervention: Mobile closed-loop control (CLC) system
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 127
Study: 28708716

Group type: EXPERIMENTAL
Intervention: Iodixanol-320 (iso-osmolar group)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Iomeprol-370 (low-osmolar group)
Number of subjects: 389
Study: 26911400

Group type: EXPERIMENTAL
Intervention: Triamcinolone (10 mg/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Verapamil (2.5 mg/ml)
Number of subjects: 14
Study: 25002723

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Docetaxel 15 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Number of subjects: 238

Group type: COMPARATOR
Intervention: Cisplatin arm versus control from RTOG-9501 trial
Number of subjects: 238

Group type: COMPARATOR
Intervention: Docetaxel arm versus control from RTOG-9501 trial
Number of subjects: 238
Study: 22612007

Group type: EXPERIMENTAL
Intervention: Limited open carpal tunnel release using direct vision and tunneling technique (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard open carpal tunnel release (group B)
Number of subjects: 28
Study: 20955444

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.d.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg od before breakfast
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg od before breakfast
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg od before dinner or at bedtime
Number of subjects: 7
Study: 18572351

Group type: EXPERIMENTAL
Intervention: 100 mL of 10% dextran-40
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 16138948

Group type: EXPERIMENTAL
Intervention: Implantable defibrillators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Device therapy
Number of subjects: 0
Study: 12436372

Group type: EXPERIMENTAL
Intervention: Glucocorticoids and non-steroidal antirheumatic drugs (NSAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMARDs (methotrexate, leflunomide, hydroxy/chloroquine, sulfasalazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF-alpha-inhibiting drugs (etanercept, infliximab)
Number of subjects: 0
Study: 11147027

Group type: EXPERIMENTAL
Intervention: 750 micrograms Fluticasone propionate (FP) twice daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study: 9176748

Group type: EXPERIMENTAL
Intervention: Intrapleurally instilled mitoxantrone (30 mg)
Number of subjects: 29
Study: 8245082

Group type: EXPERIMENTAL
Intervention: New blunt taperpoint needle
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard cutting needle
Number of subjects: 69
Study: 3988967

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: doxepin
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 31356580

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (34-35°C)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Normothermia (36.5-37.5°C)
Number of subjects: 370
Study: 29208550

Group type: EXPERIMENTAL
Intervention: Salvage surgery
Number of subjects: 30
Study: 27229685

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (PPSV23)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (2011-2012 trivalent seasonal)
Number of subjects: 125
Study: 24763885

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat hypocaloric diet (Diet M)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat hypocaloric diet (Diet P)
Number of subjects: 306